Octanate (Human Coagulation Factor Viii)

Human Coagulation Factor VIII, the active ingredient in Octanate, is a coagulation factor replacement therapy presented as a sterile solution for intravenous use. It replaces deficient clotting factor in patients with hemophilia A, helping to prevent and control bleeding episodes. GNH USA supplies Octanate as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and clinics worldwide.

GNH USA supplies Octanate as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and clinics worldwide.

Octanate is a recombinant factor VIII product used in the management of bleeding disorders related to the coagulation cascade. - Hemophilia A (severe): Provides factor VIII replacement to prevent and control spontaneous bleeding episodes. - Hemophilia A (moderate): Supports routine prophylaxis to reduce the frequency of bleeding events. - Hemophilia A (mild): Used on demand for breakthrough bleeding or surgical procedures. - Acquired hemophilia A: Supplies exogenous factor VIII to aid in hemostasis during treatment of the condition.

Adverse reactions to Octanate may vary in frequency and severity.

Common Side Effects: - Headache - Fever - Nausea - Injection site erythema - Mild arthralgia - Transient elevation of ALT enzymes

Serious or Rare Side Effects: - Development of inhibitors against factor VIII - Anaphylactic reaction or severe allergic reaction to the product itself or excipients of the  ...  ... ... ... ... ... ... ... "); -  ...  ... ");